QUOTE AND NEWS
DailyFinance  Apr 9  Comment 
AMES, IA -- (Marketwired) -- 04/09/14 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with...
DailyFinance  Mar 25  Comment 
AMES, IA -- (Marketwired) -- 03/25/14 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with...
StreetInsider.com  Mar 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NewLink+%28NLNK%29+Plans+Two+Posters+at+AACR+2014/9312653.html for the full story.
SeekingAlpha  Mar 12  Comment 
NewLink Genetics Corp. (NLNK) Q4 2013 Earnings Conference Call March 11, 2014 04:30 PM ET Executives Charles Link - CEO and CSO Nick Vahanian - President and CMO Gordon Link - CFO Analysts Mara Goldstein -Fitzgerald ...
DailyFinance  Mar 11  Comment 
AMES, IA -- (Marketwired) -- 03/11/14 -- NewLink Genetics Corporation (NASDAQ: NLNK), today reported consolidated financial results for the fourth quarter and year end 2013 and reviewed key 2013 accomplishments. "We achieved a major...
TheStreet.com  Mar 7  Comment 
 NEW YORK (TheStreet) -- NewLink Genetics and Northwest Biotherapeutics announced results from interim analyses of their respective phase III cancer studies Friday. Both studies continue as planned. Good news? Not really. Let's discuss. The...
FierceBiotech  Mar 7  Comment 
After an interim analysis, NewLink Genetics is planning to keep on keeping on with a Phase III study of its cancer vaccine. But that news came as an apparent disappointment to investors, who hoped the drug's promise would result in an early trial...
Benzinga  Mar 7  Comment 
Analogic (NASDAQ: ALOG) shares dropped 11.20% to $85.75 in pre-market trading after the company reported downbeat Q2 earnings. NewLink Genetics (NASDAQ: NLNK) shares fell 7.14% to $35.00 in the pre-market trading after the company's independent...
DailyFinance  Mar 7  Comment 
AMES, IA -- (Marketwired) -- 03/07/14 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with...
StreetInsider.com  Mar 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NewLink+Genetics+%28NLNK%29+Continues+Phase+3+IMPRESS/9258137.html for the full story.




 
TOP CONTRIBUTORS

NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical which develops drugs to help treat cancer patients.[1] The company focuses on immunotherapy - or treatment by causing the immune system to either act or cease to act. In other words, NewLink Genetics attempts to encourage the patients immune system to combat the cancerous cells rather than attempting to kill the cells directly.[2] NewLink Genetics revenues are dependent on the discovery and FDA approval of its therapies.

Business Overview

For the full year 2010, NewLink generated $2.1M in grant revenue. This was an over 100% increase from the $.9M in 2009. Since the company spends heavily on research and development, it still reported a net loss for 2010 of $16.6M. This compares to a net loss of $10.2M in 2009. [3]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on November 10, 2011. The company offered 6.2M shares each for $7. The company had already planned to sell 5.5M shares. However, since they priced below the $10-$12 range, they increased shares. The deal raised a total of $43M. The lead mangers of the deal were Stifel Financial (SF) and Canaccord Genuity.[4]

Trends & Forces

Dependence on FDA approval

As of its IPO, NewLink did not have any FDA approved drugs. It's quite clear that without a completed drug, the company will be unable to produce substantial operating revenue. As a result, the company's performance is limited to actions from the FDA. Furthermore, since NewLink is in the process of developing new, untested treatments, there is no clear guidance for the likelihood of approval or the likelihood that physicians will adopt new treatments.[5]

  1. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Overview p. 1
  2. American Cancer Society - Find Support and Treatment "Immunotherapy"
  3. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Selected Financial Data p. 51
  4. Renaissance Capital - IPO Home "NewLink Genetics prices IPO at $7, below the range" 11 Nov 2011
  5. NLNK S-1/A 2011 PROSPECTUS SUMMARY "Risk Factors" pp. 11-15
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki